1. Introduction {#sec0005}
===============

Four different families of animal viruses have been identified as the etiological agents of severe enteritis in dogs: Canine Parvovirus (CPV), Canine Coronavirus, Canine Rotavirus and Canine Distemper Virus ([@bib0145], [@bib0190], [@bib0045]). Because of the severity of the disease and its rapid spread throughout the canine population, CPV has arisen a great deal of public interest.

CPV is a non-enveloped virus with a single-stranded DNA genome of approximately 5000 bases which encodes two structural (VP1 and VP2) and two non-structural (NS1 and NS2) proteins ([@bib0030]).

CPV was first identified in May 1978 as a new virus infecting dogs ([@bib0165], [@bib0120]). In the late 1970s and early 1980s both live and inactivated Feline Panleukopenia (FPL) vaccines were used to protect dogs against CPV disease. However the level of protection they afforded was poor and the duration of immunity was short. These vaccines were replaced by live attenuated CPV vaccines, which provided good protection and longer lasting immunity ([@bib0205]).

Some biological properties of the virus, particularly its rate of nucleotide substitution which is closer to that of RNA viruses (aprox. 10^−3^/10^−4^) than to that of double-stranded DNA viruses ([@bib0200]), determined the continuous appearance of new variants with high sanitary impact in the vaccinated and unvaccinated dog populations. Two antigenic variants, named CPV2a and CPV2b, appeared a few years after the discovery of the first characterized CPV2.

Currently, the original CPV2 strain is not circulating in dog populations, although it is still present in vaccine formulations, whereas the variants CPV2a and CPV2b are distributed worldwide ([@bib0160], [@bib0125], [@bib0080], [@bib0145], [@bib0015], [@bib0040], [@bib0090], [@bib0195], [@bib0210], [@bib0220], [@bib0180], [@bib0025], [@bib0010], [@bib0130], [@bib0140], [@bib0225], [@bib0135]).

CPV2a, differs from the original type 2 strain in the presence of five amino acid (aa) changes in the VP2 coat protein, while the antigenic differences observed in CPV2b are the consequence of only one aa substitution (Asn426Asp), located in the major antigenic site of the capsid (epitope A) ([@bib0160]).

A new antigenic variant, carrying the aa substitution Asp426Glu, in the major antigenic site of the viral capsid of the VP2 protein, was reported in Italy in the year 2001 ([@bib0010], [@bib0085]). This newest variant -designated CPV2c- has already been detected in other European countries, as well as in Asia, Africa and America ([@bib0045], [@bib0060], [@bib0150], [@bib0120], [@bib0130], [@bib0055], [@bib0100], [@bib0185], [@bib0110], [@bib0020], [@bib0155]).

It is important to emphasize that the updating of methodologies by incorporation of the Minor Groove Binder probe technology, as well as PCR amplification followed by sequencing, allowed a precise identification of emerging CPV variants, therefore becoming important tools for the study of CPV epidemiology ([@bib0070], [@bib0075], [@bib0065]).

In the present study, we report an update of the identification and characterization of different CPV variants in Argentina.

2. Materials and methods {#sec0010}
========================

2.1. Clinical specimens {#sec0015}
-----------------------

A total of 79 rectal swabs samples were obtained from domestic dogs from the Argentine cities of Buenos Aires (*n*  = 50), Dolores (*n*  = 2), Tandil (*n*  = 4), Pehuajó (*n*  = 1), Mar del Plata (*n*  = 1), Bahía Blanca (*n*  = 12), Córdoba (*n*  = 2), Misiones (*n*  = 1) and Río Negro (*n*  = 3), located 216, 350, 370, 400, 690, 710, 1060, and 1500 Km from Buenos Aires, respectively. A sample from Paraguay was also analyzed while the origin of two other samples was unknown.

Clinical specimens were submitted to our laboratory for diagnostic purposes between the years 2008 and 2010. Information about the animals whose samples tested positive for CPV, such as clinical symptoms, age, gender, breed and vaccination status, is provided in [Table 1](#tbl0005){ref-type="table"} .Table 1Age, gender, vaccination records and clinical signs of dogs infected with CPV.StrainYearAge (months)SexBreedVaccination statusClinical signsCPV strainOriginaa at 440Arg1920082MRV (C)+CPV2cBuenos AiresTArg2020082NAADV (C)+CPV2cBahía BlancaTArg2120082NAADV (C)+CPV2cBahía BlancaTArg2220082NAADV (C)+CPV2cBahía BlancaTArg2320082NAADV (C)+CPV2cBahía BlancaTArg2420085MMBV (C)+CPV2cBuenos AiresTArg2520082FMSV (C)+CPV2cTandilTArg2620082MGSV (C)+CPV2cRío NegroTArg2720082MGSV (C)+CPV2cRío NegroTArg2820084FMPV (C)+CPV2cBuenos AiresTArg2920083MGPV (C)+CPV2cBuenos AiresTArg30200819MGPV (C)+CPV2aBuenos AiresTArg3120084MSFTV (C)+CPV2cBahía BlancaTArg3220081MPNV+CPV2cBuenos AiresTArg3320083FADV (C)+CPV2cCórdobaTTArg342008NANAMSNANACPV2cBuenos AiresTArg3520084MFTV (C)+CPV2cTucumanTArg362008NANAPiV (NA)NACPV2aBuenos AiresTArg3720093FBDV (NA)NACPV2cBuenos AiresTArg3820093FMBNV+CPV2cBuenos AiresTArg3920093FMBNV+CPV2cBuenos AiresTArg4020091MDNV+CPV2cBuenos AiresAArg4120092FMSV (C)+CPV2cBuenos AiresAArg42200912MMPV (C)+CPV2cBuenos AiresTArg4320093FCV (C)+CPV2cBuenos AiresAArg4420093MBV (C)+CPV2cBuenos AiresTArg452009NAFRNV+CPV2cBuenos AiresTArg4620093MBDV (C)+CPV2bBuenos AiresTArg4720094FPBNV+CPV2cBuenos AiresTArg4820096FLRV (C)+CPV2cBuenos AiresAArg4920093FMBNV+CPV2cBuenos AiresAArg5020091MGV (C)+CPV2bDoloresTArg5120091FGV (C)+CPV2bDoloresTArg5220092MLRNV+CPV2cBuenos AiresAArg5320092FMPV (C)+CPV2cBuenos AiresAArg5420098MMPV (C)+CPV2cBuenos AiresAArg552009NANAYTV (NA)NACPV2cBuenos AiresAArg5620092MBV (C)+CPV2cBuenos AiresAArg5720097MGSV (C)+CPV2cBuenos AiresAArg5820092FSFTV (C)+CPV2cBahía BlancaTArg5920091MMPV (C)+CPV2cNAAArg6020092FBeaNV+CPV2cBuenos AiresAArg6120095MMBV (C)+CPV2cCórdobaTTArg6220094MRRV (C)+CPV2cMisionesTPy120094MNMV (NA)+CPV2cParaguayAArg6320102MGRV (C)+CPV2cNATArg642010NANASFTNANACPV2cBahía BlancaTArg652010NANASFTNANACPV2cBahía BlancaTArg 6620105FBeaV (C)+CPV2cBuenos AiresAArg672010NAFMSV (C)+CPV2cBuenos AiresAArg 6820103MMSV (C)+CPV2cMar del PlataTArg 6920102MPugV (C)+CPV2cBuenos AiresAArg 7020102FGRV (C)+CPV2cBuenos AiresAArg 7120102MPV (C)+CPV2cBuenos AiresAArg 7220104MSFTV (C)+CPV2cBahía BlancaT[^1]

2.2. Preparation of samples for PCR analysis {#sec0020}
--------------------------------------------

CPV genomic DNA was extracted directly from rectal swabs and from a commercial vaccine (Vanguard^®^ Plus CPV, Pfizer), in a lysis buffer containing 50 mM Tris--HCl pH 8, 100 mM NaCl, 25 mM sucrose, 10 mM EDTA and 1% SDS. After lysis, the extracts were digested with proteinase K (Invitrogen^®^, USA) at 56 °C for 30 min and the DNAs were extracted with phenol--chloroform.

2.3. Primers and PCR amplification {#sec0025}
----------------------------------

For the amplification of a large fragment of the VP2 capsid protein-encoding gene of CPV, the *555for/555rev* primer set (5′-CAGGAAGATATCCAGAAGGA-3′/5′-GGTGCTAGTTGATATGTAATAAACA-3′), was used. The resulting product (583 bp), comprises at least six or seven informative aa responsible for important biological properties of the virus ([@bib0010]).

PCR amplification was performed using Taq recombinant polymerase (Invitrogen, USA) in an MJ Research cycler (PTC-100, Sierra Point, CA), with an initial denaturation step at 94 °C for 10 min, followed by 40 cycles of PCR (94 °C for 30 s, 50 °C for 60 s, and 72 °C for 60 s). The final concentration of MgCl~2~ was 1.5 mM.

2.4. Sequencing of the amplified DNA {#sec0030}
------------------------------------

The DNA fragments amplified from clinical samples were directly sequenced by the dideoxy-mediated chain-termination method (Macrogen Inc., Korea). Multiple sequence alignment analysis was performed using ClustalW.

The GenBank accession numbers of the aa and nucleotide sequences of reference CPV strains are: CPV-b strain (CPV2, [M38245](ncbi-n:M38245)); CPV-15 strain (CPV2a, [M24003](ncbi-n:M24003)); CPV-39 strain (CPV2b, [M74849](ncbi-n:M74849)) and 56/00 (CPV2c, [FJ222821](ncbi-n:FJ222821)).

The GenBank accession numbers of the nucleotide sequences of the DNA fragments amplified from local variants are: HQ589341, HQ589342, HQ445626, HQ450025, HQ450027, HQ45002, and HQ450029 (sample from Paraguay). For practical purposes, identical sequences were grouped, and only one of them was registered in the database.

3. Results {#sec0035}
==========

3.1. CPV detection by PCR {#sec0040}
-------------------------

During this study, 79 rectal swabs samples from animals suspected of CPV infection were tested. CPV specific DNA was detected by PCR amplification of a 583 bp fragment, in 55 out of 79 (69.6%) analyzed rectal swabs. The DNA extracted from a commercial vaccine was used as positive control. In all cases, the obtained PCR products were analyzed electrophoretically, and no differences were found in the size of the amplicons (data not shown).

Negative samples were assayed twice to confirm the results. Forty-nine out of 55 positive animals (96%) showed clinical symptoms compatible with CPV, while no records were available for the other six dogs. Interestingly, most of the positive samples (78.2%) were recovered from 1 to 5 months old puppies ([Table 1](#tbl0005){ref-type="table"}). Forty-three of them (78%) were obtained from puppies which had been vaccinated against CPV at least once, whereas eleven (20%) were obtained from unvaccinated dogs, and the vaccination status of the remaining dog was unknown.

No relationship could be established regarding sex or breed ([Table 1](#tbl0005){ref-type="table"}).

3.2. Identification of CPV variants by DNA sequencing {#sec0045}
-----------------------------------------------------

In order to identify and differentiate CPV variants in local clinical samples, the PCR products from all the positive samples were sequenced and the deduced aa sequences were aligned.

[Fig. 1](#fig0005){ref-type="fig"} shows the results of the sequence alignment from the position 407--456 of VP2, derived from seven representative local field samples identified as CPV2a, CPV2b and CPV2c, along with the sequences of the vaccine strain (CPV2) and three international reference strains. At the 426 position CPV2a variants showed an Asn (N), CPV2b an Asp (D) whereas the CPV2c variants showed a Glu (E) residue. Similar analysis performed with all the CPV positive samples, revealed that 50 out of 55 (91%) carried the Asp426Glu mutation, characteristic of the CPV2c variant, whereas two samples were characterized as CPV2a, and the remaining three, were defined as CPV2b (data not shown). In addition, the aa alignments performed with the complete 583 bp, amplification products, showed a low degree of variation (≤1%) among the Argentine CPV2c variants. This observation is in accordance with previous reports from other authors ([@bib0060], [@bib0120], [@bib0175]).Fig. 1Alignment of the deduced amino acid sequences of a fragment of the 583 bp amplicon of the VP2 gene amplified by PCR from clinical samples (aa 407--456). The aligned sequences correspond to a vaccine strain (CPV2, M38245), a CPV2a reference strain (CPV2a, M24003), a CPV2b reference strain (CPV2b M74849), an Italian CPV2c strain (FJ222821.1), and Argentine CPV2a, CPV2b and CPV2c variants. The positions 426 and 440 are highlighted.

From the results shown in [Fig. 2](#fig0010){ref-type="fig"} and [Table 1](#tbl0005){ref-type="table"}, it is clear that all CPV2 variants are at present affecting the Argentine dog population. However since the year 2008 CPV2c has become the predominant variant considering that 91% of the positive samples belonged to this variant, whereas CPV2a and CPV2b were represented only in 3.6% and 5.4% of the clinical samples, respectively.Fig. 2Updating of the evolution of CPV variants in Argentina. The number of cases detected in the years 2002--2010 belonging to each CPV variant are shown on top of the bars (previous study, [@bib0020]). \*Up to October 2010. White bars, CPV2a variants; black bars, CPV2b variants; grey bars, CPV2c variants.

3.3. A potentially relevant aminoacidic change {#sec0050}
----------------------------------------------

Besides the aa substitution at the 426 position, analysis of the sequences of Argentine CPV variants, showed the appearance of a new mutation, T440A, which is restricted to the CPV2c local variants, and whose worldwide presence has been recently reported ([@bib0060], [@bib0120], [@bib0100], [@bib0035], [@bib0115]).

The analysis performed, clearly demonstrated that 100% of the samples characterized as CPV2c obtained in 2008, presented the typical aa T at the 440 position, whereas 58% and 50% of the CPV2c samples obtained in 2009 and 2010, respectively, showed the presence of a new aa substitution (T440A), indicating that the variant CPV2cA440 has been introduced recently in the Argentine dog population.

3.4. Age distribution of CPV2c variant {#sec0055}
--------------------------------------

As can be seen in [Fig. 3](#fig0015){ref-type="fig"} , the distribution of the CPV2c variant according to age clearly shows that the majority of the puppies (86%) affected by this variant were between 1 and 5-month-old, with most of the samples belonging to 2 month-old puppies.Fig. 3Distribution of the CPV2c variants in Argentine dogs, according to age.

4. Discussion {#sec0060}
=============

The present work represents an updating of the incidence of different CPV variants in Argentina, including the cases characterized in a previous report ([@bib0020]). Although CPV2c was first detected in 2003, the results presented herein clearly show that CPV2c has become the predominant variant since the year 2008, as 91% of the samples analyzed were found to carry the typical aa substitution Glu426 ([Table 1](#tbl0005){ref-type="table"} and [Fig. 2](#fig0010){ref-type="fig"}). An additional mutation located at an exposed domain of the VP2 capsid protein (Glu426-Ala440) was also found in some of the CPV2c samples ([Fig. 1](#fig0005){ref-type="fig"}), which is in agreement with previous reports ([@bib0060], [@bib0120], [@bib0100], [@bib0035], [@bib0115]). It is interesting to point out that this mutation was found exclusively in samples collected during the years 2009 and 2010, indicating its recent appearance in the Argentine dog population.

The correlation of the T440A substitution with biological properties of the virus is still unknown, but since it is located at an important VP2 domain, exposed to selective pressure of vaccine or colostral antibodies, epidemiological surveillance is required to investigate the evolution, behavior and eventual sanitary impact of the viruses carrying this mutation ([@bib0095], [@bib0105]).

Except for the two relevant aa substitutions mentioned, a low degree of variability (≤1%) was found in the VP2 sequences of CPV2c Argentine field variants. This observation is in agreement with previous reports from other regions of the world ([@bib0060]).

It has been reported that dogs infected with the newest CPV2c variant showed frequently atypical clinical symptoms, thus making the diagnosis of CPV disease difficult ([@bib0050]). In addition, classical diagnostic procedures are not suitable for precise CPV strain identification. The traditional PCR amplification of a 583 bp fragment showed to be effective in the detection of CPV DNA, but as the size PCR products derived from CPV2, CPV2a, CPV2b and CPV2c are indistinguishable from each other; sequencing is mandatory to allow the precise identification of each variant.

The clinical samples analyzed in this work were obtained from a population composed predominantly by young puppies, and were submitted to our laboratory by associated dog breeder\'s veterinarians. Our results clearly showed that the higher incidence of CPV2c was in 1--5-month-old puppies, with a peak in 2-month-old animals ([Fig. 3](#fig0015){ref-type="fig"}). The vaccination status of this particular population was variable, with animals who had received only one or up to three doses of vaccine.

Although these findings need further confirmation by analyzing a larger number of animals, it may be speculated that at an early age there is a weakness or even a gap in the protective status of the puppies, probably due to low levels of maternal antibodies, or to the presence of an immature immune system, unable to respond properly to vaccination. Similar results were reported by our laboratory in the case of calf neonatal diarrhea caused by rotavirus ([@bib0005]). A strong increase in the level of colostral antibodies was demonstrated in this case through immunization of pregnant dams 40 days prior to delivery or by feeding exposed calves with hyperimmune colostrum. Therefore, vaccination of pregnant bitches might also increase the specific colostral and milk antibody levels in dogs, which can help dealing with the CPV2c infections in young puppies. Another possibility might be the development of improved vaccines or the updating of the vaccination schedules, in order to induce effective early protective responses.

Canine Parvovirus evolution and its rapid spreading through dog populations, raises concerns among breeders, owners and veterinary practitioners about the need of updating current CPV vaccines ([@bib0215]). In addition, complementary sanitary measures, such as increasing the biosecurity levels of the breeding premises and the implementation of stronger sanitary regulations in the trade or exhibitions of live dogs, could also be relevant.
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[^1]: F: female; M: male; MB: Mixed Breed; GR: Golden Retriever; LR, Labrador Retriever; GS: German Shepherd; R: Rottweiler; D: Doberman; AD: Argentine Dogo; MS: Miniature Schnauzer; FT: Fox Terrier; YT: Yorkshire Terrier; SFT: Smooth Fox Terrier; C: Cocker; P: Poodle; MP: Miniature Poodle; B: Boxer; Bea: Beagle; BD: Bulldog; Pi: Pinscher; PB: Pitbull; G: Greyhound; NM: Neapolitan Mastiff; RR: Rhodesian Ridgeback; GP: Giant Poodle. V: vaccinated; NV: no vaccinated; NA: no information available. C: complete vaccination according to its age.
